W. Meyer

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
W. Meyer, W. A. Meyer, W A Meyer, William A. Meyer, William Meyer, William A Meyer, Williama. Meyer
Publication record
88 papers · 6,267 citations · H-index 37

PAPERS

Immunocompetent and immunocompromised cancer populations: Post-vaccination humoral and cellular immune responses against SARS-CoV-2.
20230 citationsauthor #16
Hepatitis C Virus Clearance Cascade — United States, 2013–2022
202336 citationsauthor #5
Correlates of immunity in SARS-CoV-2 post-vaccine infections in the Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) Study
20230 citationsauthor #8
Immune and behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection
20237 citationsauthor #3
Risk of and duration of protection from SARS-CoV-2 reinfection assessed with real-world data
20237 citationsauthor #3
SARS-CoV-2 spike-protein targeted serology test results and their association with subsequent COVID-19-related outcomes
20235 citationsauthor #3
Insights into HIV-1 Transmission Dynamics Using Routinely Collected Data in the Mid-Atlantic United States
20222 citationsauthor #7
Hepatitis C Virus Testing During Pregnancy After Universal Screening Recommendations
202215 citationsauthor #3
Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States—October 25, 2020–February 26, 2022
202251 citationsauthor #5
Assessing Vulnerability to COVID-19 in High-Risk Populations: The Role of SARS-CoV-2 Spike-Targeted Serology
20226 citationsauthor #2
Duration of Protection Against SARS-CoV-2 Reinfection and Associated Risk of Reinfection Assessed with Real-World Data
20223 citationsauthor #3
Prevalence of Hepatitis B Virus and Latent Tuberculosis Coinfection in the United States
20226 citationsauthor #4
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection
2021241 citationsauthor #7
Minority and Rural Coronavirus Insights Study (MRCIS): The Need for Targeted COVID-19 Vaccination Efforts in Minority Populations
20210 citationsauthor #7
TaggedH1 Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic TaggedEnd
202170 citationsauthor #3
S3407 Testing Patterns and Prevalence of Latent Tuberculosis Co-Infection Among Patients With Chronic Hepatitis B Virus Infection
20210 citationsauthor #4
Retrospective Performance Analyses of over Two Million U.S. QuantiFERON Blood Sample Results
202110 citationsauthor #7
Detection of SARS-CoV-2 IgG Targeting Nucleocapsid or Spike Protein by Four High-Throughput Immunoassays Authorized for Emergency Use
202032 citationsauthor #8
Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a decreased risk of future infection
202025 citationsauthor #7
Insights from Patterns of SARS-CoV-2 Immunoglobulin G Serology Test Results from a National Clinical Laboratory, United States, March–July 2020
202015 citationsauthor #3
Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020
2020277 citationsauthor #16
Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial
201832 citationsauthor #13
Blood Lead Levels and Neurodevelopmental Function in Perinatally HIV-Exposed, Uninfected Children in a U.S.-Based Longitudinal Cohort Study
20172 citationsauthor #9
Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults with HIV Infection Being Treated with Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial
20174 citationsauthor #13
Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine.
201730 citationsauthor #6
Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia
201711 citationsauthor #4
Antiretroviral Drug Resistance Among Children and Youth in the United States With Perinatal HIV.
201634 citationsauthor #6
Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC.
201640 citationsauthor #12
Determination of HIV-1 coreceptor tropism using proviral DNA in women before and after viral suppression
20156 citationsauthor #9
Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection.
201527 citationsauthor #7
Assessment of Biomarkers of Cardiovascular Risk Among HIV Type 1-Infected Adolescents: Role of Soluble Vascular Cell Adhesion Molecule As an Early Indicator of Endothelial Inflammation
201333 citationsauthor #4
Use of rapid HIV assays as supplemental tests in specimens with repeatedly reactive screening immunoassay results not confirmed by HIV-1 Western blot.
201311 citationsauthor #3
Performance of a fourth-generation HIV screening assay and an alternative HIV diagnostic testing algorithm
201349 citationsauthor #3
Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians
2013341 citationsauthor #10
Delaney et al. respond to Dr. Apfelroth
20120 citationsauthor #4
Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children.
201260 citationsauthor #6
Change in High-Sensitivity C-Reactive Protein Levels Following Initiation of Efavirenz-Based Antiretroviral Regimens in HIV-Infected Individuals
201137 citationsauthor #5
Vitamin D Deficiency in HIV-Infected and HIV-Uninfected Women in the United States
201193 citationsauthor #11
Performance of an alternative laboratory-based algorithm for diagnosis of HIV infection utilizing a third generation immunoassay, a rapid HIV-1/HIV-2 differentiation test and a DNA or RNA-based nucleic acid amplification test in persons with established HIV-1 infection and blood donors.
201130 citationsauthor #7
Performance of an alternative laboratory-based algorithm for HIV diagnosis in a high-risk population.
201119 citationsauthor #5
Associations of Proinflammatory Cytokine Levels With Lipid Profiles, Growth, and Body Composition in HIV-infected Children Initiating or Changing Antiretroviral Therapy
201034 citationsauthor #5
Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old
2010186 citationsauthor #5
Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIV.
201035 citationsauthor #7
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
2010244 citationsauthor #7
Treatment Interruption after Pregnancy: Effects on Disease Progression and Laboratory Findings
200937 citationsauthor #5
Antiretroviral Exposure and Lymphocyte mtDNA Content Among Uninfected Infants of HIV-1-Infected Women
200955 citationsauthor #9
Morphologic and metabolic abnormalities in vertically HIV-infected children and youth
2009102 citationsauthor #8
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.
2008197 citationsauthor #5
Lipid and Glucose Alterations in HIV-Infected Children Beginning or Changing Antiretroviral Therapy
200863 citationsauthor #5
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
200744 citationsauthor #9
HIV-1 drug resistance in variants from the female genital tract and plasma.
200736 citationsauthor #12
Endocrine Abnormalities and Impaired Growth in Human Immunodeficiency Virus–Infected Children
200723 citationsauthor #3
Metabolic Effects of Protease Inhibitor-Sparing Antiretroviral Regimens Given as Initial Treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)
200760 citationsauthor #4
Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.
2006172 citationsauthor #18
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
2006233 citationsauthor #6
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides
2005206 citationsauthor #10
Triple nucleoside analogue vs. efavirenz-containing regimens for the initialtreatment of HIV infection: AIDS Clinical Trials Group (ACTG) Study A5095
200424 citationsauthor #6
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
2004535 citationsauthor #6
Performance Characteristics of HIV-1 Culture and HIV-1 DNA and RNA Amplification Assays for Early Diagnosis of Perinatal HIV-1 Infection
200387 citationsauthor #6
HIV-1 in genital tract and plasma of women: Compartmentalization of viral sequences, coreceptor usage, and glycosylation
2003129 citationsauthor #13
Progression of HIV Disease Among Women Following Delivery
200352 citationsauthor #7
Vitamin A deficiency and genital viral burden in women infected with HIV-1.
200210 citationsauthor #7
Effectiveness of highly active antiretroviral therapy among HIV-1 infected women
200273 citationsauthor #9
Longitudinal Variability of Human Immunodeficiency Virus Type 1 RNA Viral Load Measurements by Nucleic Acid Sequence-Based Amplification and NucliSens Assays in a Large Multicenter Study
200114 citationsauthor #4
Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.
200188 citationsauthor #6
Quantification of human immunodeficiency virus type 1 p24 antigen and antibody rivals human immunodeficiency virus type 1 RNA and CD4+ enumeration for prognosis
200012 citationsauthor #7
Serum vitamin A concentrations in a North American cohort of human immunodeficiency virus type 1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
199917 citationsauthor #4
Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.
1999157 citationsauthor #13
Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
199940 citationsauthor #4
RISK FACTORS FOR PERINATAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN WOMEN TREATED WITH ZIDOVUDINE
1999590 citationsauthor #5
Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission.
199967 citationsauthor #5
The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women's interagency HIV study.
199963 citationsauthor #10
Serum Vitamin A Concentrations in a North American Cohort of HIV-Infected Children † 541
19980 citationsauthor #4
Determinations of Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma: Reassessment of Parameters Affecting Assay Outcome
199877 citationsauthor #17
Evaluation of HIV1 infection status by HIV1 PCR and culture methodologies in a small cohort of intravenous drug users.
19971 citationsauthor #4
The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
199776 citationsauthor #3
Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group.
199713 citationsauthor #6
Safety and Pharmacokinetics of Hyperimmune Anti-Human Immunodeficiency Virus (HIV) Immunoglobulin Administered to HIV-Infected Pregnant Women and Their Newborns
199761 citationsauthor #6
The Relationship between Serum Human Immunodeficiency Virus Type 1 (HIV-1) RNA Level, CD4 Lymphocyte Percent, and Long-Term Mortality Risk in HIV-1—Infected Children
1997253 citationsauthor #3
Change overtime in neopterin (NPT) & beta-2 microglobuun (B-2M) in HIV-infected children followed in the nichd ivig cunical trial: Correlation between measures association with mortality risk
19960 citationsauthor #4
Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
1994221 citationsauthor #7
Detection of HIV-1 by polymerase chain reaction and culture in seronegative intravenous drug users in an inner-city emergency department.
199311 citationsauthor #3
Clinical, Virologic, and Immunologic Effects of Combination Therapy with Ribavirin and Isoprinosine in HIV‐Infected Homosexual Men
19905 citationsauthor #5
Clinical, virologic, and immunologic effects of combination therapy with ribavirin and isoprinosine in HIV-infected homosexual men
19902 citationsauthor #5
A phase 1 study of ribavirin in human immunodeficiency virus-infected patients.
199026 citationsauthor #3
Effect of lithium carbonate in HIV-infected patients with immune dysfunction.
198826 citationsauthor #4
Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex.
1987104 citationsauthor #20
A sensitive solution hybridization technique for detecting RNA in cells: Application to HIV in blood cells
198736 citationsauthor #3

TIMELINE

1987 140 citations

1988 26 citations

1990 33 citations

1993 11 citations

1994 221 citations

1996 0 citations

1997 404 citations

1998 77 citations

1999 934 citations

2000 12 citations

2001 102 citations

2002 83 citations

2003 268 citations

2004 559 citations

2005 206 citations

2006 405 citations

2007 163 citations

2008 260 citations

2009 194 citations

2010 499 citations

2011 179 citations

2012 60 citations

2013 434 citations

2015 33 citations

2016 74 citations

2017 47 citations

2018 32 citations

2020 349 citations

2021 321 citations

2022 83 citations

2023 55 citations

W. Meyer

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT